Drug Type Small molecule drug |
Synonyms Modafinil/flecainide, THN-102 |
Target |
Mechanism DAT antagonists(Dopamine transporter antagonists), SCNA modulators(Sodium channel alpha subunit modulators) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H24F6N2O5 |
InChIKeyRKXNZRPQSOPPRN-UHFFFAOYSA-N |
CAS Registry54143-56-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 2 | US | 12 Jul 2018 | |
Parkinson Disease | Phase 2 | CZ | 12 Jul 2018 | |
Parkinson Disease | Phase 2 | FR | 12 Jul 2018 | |
Parkinson Disease | Phase 2 | DE | 12 Jul 2018 | |
Parkinson Disease | Phase 2 | HU | 12 Jul 2018 | |
Narcolepsy | Phase 2 | BE | 01 Sep 2016 | |
Narcolepsy | Phase 2 | FR | 01 Sep 2016 | |
Sleepiness | Phase 2 | BE | 01 Sep 2016 | |
Sleepiness | Phase 2 | FR | 01 Sep 2016 | |
Sleep Deprivation | Phase 1 | - | 01 Sep 2015 |
Phase 2 | 51 | (Modafinil + Placebo) | grqianimkv(nntxtfvexd) = jllxzbpfqz npgsxrqpmq (kkebaryhva, xauecypfdu - elcyvucliz) View more | - | 04 Sep 2020 | ||
(THN102 300/3) | grqianimkv(nntxtfvexd) = veamtbxhrv npgsxrqpmq (kkebaryhva, lqeplrbegh - pbaykuqvzn) View more |